Поиск Поиск структуры
wx_img
Inquiry Form
  1. Home
  2. Adagrasib

Adagrasib

Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.

8-chloronaphthalen-1-amine
8-chloronaphthalen-1-amine
CM141452
59107-51-6
(S)-2-(piperazin-2-yl)acetonitrile
(S)-2-(piperazin-2-yl)acetonitrile
CM325414
1589082-26-7
tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate
tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate
CM104183
916420-27-4
(S)-2-(1,4-Dibenzylpiperazin-2-yl)acetonitrile
(S)-2-(1,4-Dibenzylpiperazin-2-yl)acetonitrile
CM335976
2225787-92-6
[(2S)-1-methylpyrrolidin-2-yl]methanol
[(2S)-1-methylpyrrolidin-2-yl]methanol
CM328420
34381-71-0
benzyl (2S)-2-(cyanomethyl)piperazine-1-carboxylate
benzyl (2S)-2-(cyanomethyl)piperazine-1-carboxylate
CM328382
2158302-01-1
7-benzyl-2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine
7-benzyl-2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine
CM105615
1059735-34-0
Ethyl 1-benzyl-3-oxopiperidine-4-carboxylate
Ethyl 1-benzyl-3-oxopiperidine-4-carboxylate
CM181043
39514-19-7